Exeliom Biosciences
PrivateLast Round
Series A
Extension
Oct 21, 2025
Total Funding Raised
$28.98M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Exeliom Biosciences is a biotechnology company that develops microbiome-based immunotherapies using single bacterial strain drug candidates to treat inflammatory bowel diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Exeliom Biosciences Comparables
Compare Exeliom Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Microbiotica | 83% | |
| MRM Health | 80% | |
| Vedanta Biosciences | 77% |
Exeliom Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Oct 21, 2025 | ||||
| Grant | Mar 6, 2024 | ||||
| Grant | Nov 28, 2023 | ||||
| Series A Extension | Jul 3, 2023 | ||||
| Grant | Aug 3, 2020 | ||||
Grant | Aug 12, 2019 |
Key People
Founding team and executive leadership
Exeliom Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forepont Capital Partners | Series A Extension |
| CE-Ventures | Series A Extension |
| Sofimac Innovation | Series A |
| National Research Institute for Agriculture, Food and Environment | Series A |
| Auriga Partners | Series A Extension, Series A |
| Capital Grand Est | Series A Extension, Series A |
| Crohn's & Colitis Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors grew 288% MoM to 1.3K.
- Jul 10, 2025
Announced the launch of LIVEDIFF Part 2.
Exeliom Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Exeliom Biosciences's valuation, stock price, and market status.
Is Exeliom Biosciences a public or private company?
Exeliom Biosciences is a private company.
What is the current stock price of Exeliom Biosciences?
Exeliom Biosciences is a private company with no public stock price. No recent secondary market data is available.
How much is Exeliom Biosciences worth (valuation)?
Valuation information for Exeliom Biosciences is not publicly available.
Can I buy Exeliom Biosciences stock?
Exeliom Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Exeliom Biosciences's last funding round?
Exeliom Biosciences's most recent funding round was Grant on November 28, 2023.
Who are the main investors in Exeliom Biosciences?
Key investors in Exeliom Biosciences include Auriga Partners, CE-Ventures.
Will Exeliom Biosciences IPO soon?
No public IPO plans have been announced for Exeliom Biosciences.
How can I track Exeliom Biosciences secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Exeliom Biosciences's secondary market activity and sign up for updates.